Fig. 3 | Scientific Reports

Fig. 3

From: Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases

Fig. 3The alternative text for this image may have been generated using AI.

Comparison of PSMA expression profile between HSPC-PL and mCRPC-BML status. (A) Box plot showing the comparison of PSMA MHscore between PL and BML, PSMA expression level in BML was significant lower than PL. (B) Violin plot showing the comparison of PSMA NMR between PL and BML, PSMA NMR in BML was also significant lower than PL. (C) Waterfall plot showing the alteration of membranous PSMA expression from PL to BML, along with the corresponding treatment history heatmap (second generation androgen receptor antagonist (SGARA), chemotherapy and radiotherapy), no significant correlation was observed between PSMA alteration and any of the various treatment history. (D, E,F, G) Different patterns of intra-patient PSMA expression heterogeneity in matched samples. (D) Heterogeneously low expression in different regions of the same HSPC sample (①③: within same regions, even adjacent tumor tissues can exhibit heterogeneous PSMA expression level, the tumor tissue in the red dashed area shows absent PSMA expression;②completely absent PSMA expression tumor region), with high and uniform PSMA expression in matched mCRPC. (E) High PSMA expression in HSPC, low expression in matched mCRPC. (F) Heterogeneously low expression in both HSPC and matched mCRPC. (G) High expression in primary HSPC, heterogeneously low expression in both matched synchronously mHSPC and metachronously mCRPC. All the black scale bars in the IHC image represent 100 μm. Brown scale bars in the IHC image represent 500 μm.

Back to article page